Predicted protein targets (top 14)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | SMN1; SMN2 | Q16637 | 3/20 | 0.39 |
| ▸ | LMNA | P02545 | 2/20 | 0.39 |
| ▸ | HPGD | P15428 | 4/20 | 0.39 |
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.37 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.36 |
| ▸ | TSHR | P16473 | 1/20 | 0.36 |
| ▸ | RAB9A | P51151 | 1/20 | 0.36 |
| ▸ | CYP2D6 | P10635 | 1/20 | 0.35 |
| ▸ | CYP2C19 | P33261 | 1/20 | 0.35 |
| ▸ | PSMB5 | P28074 | 1/20 | 0.35 |
| ▸ | NPSR1 | Q6W5P4 | 1/20 | 0.35 |
| ▸ | MAPT | P10636 | 1/20 | 0.34 |
| ▸ | SPR | P35270 | 1/20 | 0.34 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.33 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL12888245 | 0.85 | SMN1; SMN2 (0.50) | SMN1; SMN2LMNAHPGDALDH1A1KMT2A | |
| SCHEMBL25646524 | 0.82 | KISS1R (0.45) | SMN1; SMN2LMNAHPGDALDH1A1KMT2A | |
| SCHEMBL25646523 | 0.82 | KISS1R (0.45) | SMN1; SMN2LMNAHPGDALDH1A1KMT2A | |
| SCHEMBL13744709 | 0.79 | HPGD (0.41) | SMN1; SMN2LMNAHPGDALDH1A1KMT2A | |
| SCHEMBL15834107 | 0.79 | HPGD (0.41) | SMN1; SMN2LMNAHPGDALDH1A1KMT2A | |
| SCHEMBL13744668 | 0.79 | HPGD (0.41) | SMN1; SMN2LMNAHPGDALDH1A1KMT2A | |
| SCHEMBL20657156 | 0.79 | MAPT (0.38) | ALDH1A1RAB9ACYP2D6CYP2C19MAPT | |
| SCHEMBL87923 | 0.78 | TSHR (0.41) | SMN1; SMN2LMNAHPGDALDH1A1KMT2A | |
| SCHEMBL87924 | 0.78 | HPGD (0.40) | SMN1; SMN2LMNAHPGDALDH1A1KMT2A | |
| SCHEMBL20016486 | 0.77 | ALDH1A1 (0.41) | LMNAHPGDALDH1A1CYP2D6CYP2C19 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20170107251-A1 | NOVEL RUTHENIUM COMPLEXES AND THEIR USES IN PROCESSES FOR FORMATION AND/OR HYDROGENATION OF ESTERS, AMIDES AND DERIVATIVES THEREOF | YEDA RESEARCH AND DEVELOPMENT CO. LTD. (IL) | 2017-04-20 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20170107251-A1 | NOVEL RUTHENIUM COMPLEXES AND THEIR USES IN PROCESSES FOR FORMATION AND/OR HYDROGENATION OF ESTERS, AMIDES AND DERIVATIVES THEREOF | ADH1C, ADH5, ADH1A | SMN1; SMN2 4864/4885LMNA 3705/4885HPGD 1272/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.